Classroom and Laboratory Safety Signs
Investigating Somatic Mutations in Pancreatic Adenocarcinoma
Edited Transcript from “The Pathway to Genomic Medicine,” Richard Gibbs, PhD*
In addition to participating in those large multi-center programs, we have an initiative with the Department of Surgery [at Baylor College of Medicine] where we’re looking at pancreatic adenocarcinoma. We’re looking at both sampling some of these candidate genes to look for mutational activity in them, but also generating the pipeline where we can reliably and meaningfully move samples from the surgical suite to the lab to get these initial diagnostic profiles. So we’re doing what I’d call a model of how one day we might have a true diagnostic pipeline that is meaningful, where you can use biopsy instead of large tumor sections, where you can use DNA amplification techniques that are novel, and have robust and meaningful results. But this is both a pretest of that model, as well as trying to inch pancreatic adenocarcinoma, and the group here of course, closer to being one of those 50 diseases at the top of the list for the national program. So those are the applications, in some of these big arenas, of using sequencing to drive the knowledge base.
* Notes in this slide presentation are adapted from the transcript of “The Pathway to Genomic Medicine,” a presentation by Richard Gibbs, PhD, given in August 2007, as part of Baylor College of Medicine’s Department of Medicine Grand Rounds Human Genetics Symposium.
Your slide tray is being processed.